Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC) has signed a non-binding letter of intent (LOI) to combine with global healthcare holding company OSR Holdings, Ltd.
Seoul, South Korea-based OSR leverages its international network of partners in the US, Europe, and South Korea to develop and license its pipeline of innovative biomedical therapies based on proprietary platform technologies, with the ultimate goal of addressing unmet medical needs.
Although Bellevue did not provide much information on the potential transaction, it expects to finalize the definitive agreement within the coming weeks and will announce additional details at that time. With a November 14 completion deadline, the parties intend to complete the business combination in the fourth quarter of 2023.
Upon completion of the business combination, the surviving company will be renamed OSR Biosciences, Inc.
OSR Holdings currently wholly owns three operating subsidiaries in Switzerland and South Korea, two of which are focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases.
Additionally, OSR Holdings signed a separate LOI on July 7 to acquire Landmark BioVentures AG, a Swiss company that operates through four different biotech ventures in France with therapeutic focuses on oncology and immunology.
Bellevue Life Sciences priced its $60 million IPO earlier this year in February and initially set out to acquire a target business in the healthcare industry, specifically in the biotechnology sector developing the next generation of biologics. The SPAC is led by CEO Kuk Hyuon Hwang, CFO David J. Yoo, and Nominee for Chairman of the Board Steven Reed.
Shepherd Ave Capital Acquisition Corp. (Nasdaq: SPHAU) is the latest SPAC to file to IPO, making 24 new registration statements that have filed since June 1, 2024. So far, only two of those 24 have gone public, but it does indicate an active August. In SPACLand at least, August is never slow. As for Shepherd...
At the SPAC of Dawn SPACs have now priced 20 IPOs seven months into 2024 with an eye on beating 2023’s total of 31 IPOs. With a little more than 5 months left in the year, it’s expected that SPACs should at least match that number by only needing to price roughly two IPOs per...
DT Cloud Star announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “DTSQU”, Thursday, July 25, 2024. The new SPAC aims to combine with an established business with long-term financial visibility, but has not limited itself to a particular industry or sector....
Launch Two (NASDAQ:LPBBU) has filed for a $200 million IPO that shows how the market has shifted for new issuance since its sister SPAC Launch One (NASDAQ:LPAAU) filed just over a month ago. Both SPACs are underwritten by Cantor Fitzgerald and seeking nominally the same raise at IPO, but Launch Two is overfunding its trust...
FTAC Emerald (NASDAQ:EMLD) has entered into a definitive agreement to combine with crypto fintech firm Fold at an enterprise value of $381 million. Phoenix, Arizona-based Fold provides digital banking services backed by a treasury of Bitcoin that includes FDIC-secured checking accounts as well Bitcoin trading and awards. The combined company is expected to trade on...